Literature DB >> 20443909

Isosorbide dinitrate and hydralazine as therapy for African Americans with heart failure; a failed paradigm?

Clyde W Yancy1, Arthur Feldman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20443909      PMCID： PMC5407473          DOI： 10.1111/j.1752-8062.2009.00130.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN： 1752-8054            Impact factor:   4.689


× No keyword cloud information.
  20 in total

1.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Authors:  Anne L Taylor; Susan Ziesche; Clyde Yancy; Peter Carson; Ralph D'Agostino; Keith Ferdinand; Malcolm Taylor; Kirkwood Adams; Michael Sabolinski; Manuel Worcel; Jay N Cohn
Journal:  N Engl J Med       Date:  2004-11-08       Impact factor: 91.245

2.  Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.

Authors:  Inder S Anand; S William Tam; Thomas S Rector; Anne L Taylor; Michael L Sabolinski; W Tad Archambault; Kirkwood F Adams; Adeoye Y Olukotun; Manuel Worcel; Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2006-12-14       Impact factor: 24.094

3.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

4.  Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.

Authors:  Derek C Angus; Walter T Linde-Zwirble; S William Tam; Jalal K Ghali; Michael L Sabolinski; Victor G Villagra; Wolfgang C Winkelmayer; Manuel Worcel
Journal:  Circulation       Date:  2005-12-13       Impact factor: 29.690

5.  HFSA 2006 Comprehensive Heart Failure Practice Guideline.

Authors: 
Journal:  J Card Fail       Date:  2006-02       Impact factor: 5.712

6.  Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure.

Authors:  Kersten M Small; Lynne E Wagoner; Albert M Levin; Sharon L R Kardia; Stephen B Liggett
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

Review 7.  Heart failure in African Americans.

Authors:  Clyde W Yancy
Journal:  Am J Cardiol       Date:  2005-08-09       Impact factor: 2.778

8.  Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.

Authors:  S William Tam; Michael L Sabolinski; Manuel Worcel; Milton Packer; Jay N Cohn
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.

Authors:  Dennis M McNamara; S William Tam; Michael L Sabolinski; Page Tobelmann; Karen Janosko; Lakshmi Venkitachalam; Elizabeth Ofili; Clyde Yancy; Arthur M Feldman; Jalal K Ghali; Anne L Taylor; Jay N Cohn; Manuel Worcel
Journal:  J Card Fail       Date:  2008-12-23       Impact factor: 5.712

10.  Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry.

Authors:  Clyde W Yancy; William T Abraham; Nancy M Albert; Robert Clare; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Lilin She; Jie Lena Sun; James B Young; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2008-04-29       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.